We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.00 | 2.07% | 296.00 | 293.00 | 296.00 | 303.00 | 298.00 | 299.00 | 53,971 | 16:35:06 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
From Apr 2023 to Apr 2024
By Anthony O. Goriainoff
Hutchmed (China) said Friday that its fruquintinib cancer treatment has been granted a priority review of the New Drug Application by the U.S. Food and Drug Administration.
The London-listed biopharmaceutical company said that if approved fruquintinib will be the first and only highly selective inhibitor of all three vascular endothelial growth factor receptors approved in the U.S. for previously treated metastatic colorectal cancer.
Hutchmed said the FDA plans to complete the review process by Nov. 30.
Fruquintinib is approved in China as a treatment for refractory metastatic colorectal cancer, the company said.
"Today's acceptance marks a significant advancement towards the goal of providing patients with previously treated metastatic colorectal cancer a much-needed therapeutic option, given the limited treatment options currently available to patients," the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
May 26, 2023 02:51 ET (06:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Hutchmed (china) Chart |
1 Month Hutchmed (china) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
